EUVIMEDDescoperă EUVIMED
ÜbersichtsarbeitOpen access

Reducing Unmet Needs in Hidradenitis Suppurativa by Including the Hair Follicle Among an Arsenal of Targets

Kyle Maas, Olivia D Perez iD, Sarah E Millar iD, Miriam K Pomeranz, Lynn Petukhova iD

Experimental Dermatology · 2026-07 · 35 (7)

DOI: 10.1111/exd.70321 ↗

At a glance

Übersichtsarbeit in Experimental Dermatology, published online on 2026-07-09. Written by Kyle Maas and 4 co-authors. Institution: Vanderbilt University School of Medicine, Nashville, Tennessee, USA. Major MEDLINE topics: Hidradenitis Suppurativa, Hair Follicle. 141 references. The full text is freely available in PubMed Central. Funded by: NIAMS NIH HHS, NIH HHS, National Institutes of Health.

RezumatSubjectsDate bibliograficeCiteRelated studies

Abstract (original language)

Hidradenitis suppurativa (HS) is a prevalent, debilitating disease affecting ~1% of the population, with limited therapeutic options and poor long‐term remission rates. HS arises from inflammation and destruction of apocrine‐bearing hair follicles, suggesting a multifactorial pathology involving immune dysregulation and follicular dysfunction. Emerging treatment strategies largely center on immune suppression, with three FDA‐approved therapies targeting inflammatory pathways. However, most patients fail to achieve durable remission. Genetic evidence increasingly implicates the hair follicle as a key contributor to HS pathogenesis. For example, genes that cause ectodermal dysplasias (EDs) have been implicated by common risk variants identified in genome‐wide association studies (GWAS) and by rare variants in sequencing studies of rare ED syndromes that co‐present with HS. EDs are Mendelian (i.e., single‐gene) disorders that disrupt the development of ectodermal derivatives, including hair follicles and sweat glands. The enrichment of ED‐associated genes in HS genetic studies, together with HS phenotypes observed in ED patients, supports a critical role for aberrant follicular development in HS pathogenesis. We propose that HS represents a spectrum of related diseases entities spanning immune dysregulation and hair follicle pathology, underscoring the need for biomarkers and refined disease classification to tailor treatment strategies. This perspective argues for broadening drug‐development programs and insurance coverage for therapeutic strategies beyond immunomodulation to include follicle‐targeted approaches.

Subjects

MeSH terms (MEDLINE)

Hidradenitis SuppurativaHair FollicleHumansGenome-Wide Association StudyEctodermal DysplasiaAnimals

Authors and institutions

  • Vanderbilt University School of Medicine, Nashville, Tennessee, USA.
  • The Ronald O. Perelman Department of Dermatology, NYU Grossman School of Medicine, New York, New York, USA.
  • Black Family Stem Cell Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • Department of Stem Cell Biology and Regenerative Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA.

ORCID profiles: Olivia D Perez, Sarah E Millar, Lynn Petukhova

Funding

  • NIAMS NIH HHS
  • NIH HHS
  • National Institutes of Health

Cite

APA

Maas, K., Perez, O. D., Millar, S. E., Pomeranz, M. K., & Petukhova, L. (2026). Reducing Unmet Needs in Hidradenitis Suppurativa by Including the Hair Follicle Among an Arsenal of Targets. Experimental Dermatology, 35(7). https://doi.org/10.1111/exd.70321

Vancouver

Maas K, Perez OD, Millar SE, Pomeranz MK, Petukhova L. Reducing Unmet Needs in Hidradenitis Suppurativa by Including the Hair Follicle Among an Arsenal of Targets. Experimental Dermatology. 2026;35(7). doi:10.1111/exd.70321

BibTeX
@article{Maas2026,
  author = {Maas, Kyle and Perez, Olivia D and Millar, Sarah E and Pomeranz, Miriam K and Petukhova, Lynn},
  title = {Reducing Unmet Needs in Hidradenitis Suppurativa by Including the Hair Follicle Among an Arsenal of Targets},
  journal = {Experimental Dermatology},
  year = {2026},
  volume = {35},
  number = {7},
  doi = {10.1111/exd.70321}
}
Start for free →